Madrigal Pharmaceuticals (MDGL) News Today

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) stock has climbed on news of expanded patent protection and technical strength, although a series of insider share sales has introduced some downward pressure.

• Positive Sentiment: Received notice of allowance from the U.S. Patent and Trademark Office for a new patent covering Rezdiffra™ (resmetirom), extending exclusivity. Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
• Positive Sentiment: Stock jumped about 11% after securing a new U.S. patent to protect Rezdiffra dosing rights through 2044. MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
• Positive Sentiment: Hit an 80-plus relative strength rating, signaling robust technical momentum. Madrigal Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark
• Neutral Sentiment: Madrigal shares rose 10.9% on higher-than-average volume, though analysts question whether the rally can be sustained. Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
• Negative Sentiment: Director Rebecca Taub sold 26,444 shares at an average price of $353.47, reducing her stake by 5.42%. Rebecca Taub Sells 26,444 Shares
• Negative Sentiment: Director Paul A. Friedman sold 26,176 shares at an average price of $353.47, trimming his holding by 12.27%. Paul A. Friedman Sells 26,176 Shares
• Negative Sentiment: Director Paul A. Friedman sold 2,700 shares at an average price of $350.48, a 1.42% reduction in his stake. Paul A. Friedman Sells 2,700 Shares
• Negative Sentiment: Director Rebecca Taub sold 2,657 shares at an average price of $350.41, trimming her position by 0.57%. Rebecca Taub Sells 2,657 Shares